Prevention of Alzheimer's Disease: Lessons Learned and Applied
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease ( AD ) affects more than 5 million Americans, with substantial consequences for individuals with AD , families, and society in terms of morbidity, mortality, and healthcare costs. With disease‐modifying treatment trials unsuccessful at the present time and only medications to treat symptoms available, an emerging approach is prevention. Advances in diagnostic criteria, biomarker development, and greater understanding of the biophysiological basis of AD make these initiatives feasible. Ongoing pharmacological trials using anti‐amyloid therapies are underway in sporadic and genetic forms of AD , although a large number of modifiable risk factors for AD have been identified in observational studies, many of which do not appear to exert effects through amyloid or tau. This suggests that prevention studies focusing on risk reduction and lifestyle modification may offer additional benefits. Rather than relying solely on large‐sample, long‐duration, randomized clinical trial designs, a precision medicine approach using N‐of‐1 trials may provide more‐rapid information on whether personalized prevention plans can improve person‐centered outcomes. Because there appear to be multiple pathways to developing AD , there may also be multiple ways to prevent or delay the onset of AD . Even if these precision approaches alone are not successful in preventing AD , they may greatly improve the likelihood of amyloid‐ or tau‐specific therapies to reach their endpoints by reducing comorbidities. Keeping this in mind, dementia may be a disorder that develops over a lifetime, with individualized ways to build a better brain as we age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 1×
“Overall between-group differences were statistically significant for global cognition, executive function, and processing speed but not episodic memory.(17) These results suggest that lifestyle modification may offer some benefit in cognitive function, albeit with a small effect size.”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506 · cited 2×
“In the absence of robust biomarkers that mark disease onset and progression, rather than just the presence of pathology, RCT design will remain a challenge.(23) Barriers to prevention studies include limited understanding of the real relationship between dementia risk factors and the effect of risk reduction; complexi…”
BackgroundDrug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459 · cited 2×
“First, only medications that have already entered Phase II testing can make it to market by 2025.(2) Second, if a DMT were available by 2025, then the 2050 projection of 16 million Americans with AD would be reduced by 5.”
BackgroundCognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities
Cheng, S.-T. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0721-2 · Cited by 385 · cited 1×
“In addition, physical activities may lead to a 20% to 65% risk reduction depending on the type and intensity of activity through mechanisms involving lower vascular disease risk, better respiratory function, stimulation of trophic factors, and lower oxidative stress and inflammation.(13) Objective measurement of midli…”
BackgroundYates, L. A., Ziser, S., Spector, A., & Orrell, M. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216001137 · Cited by 323
Lifestyle for Brain Health (LIBRA): a new model for dementia prevention
Schiepers, O. J. G., Köhler, S., Deckers, K., Irving, K., O'Donnell, C. A., van den Akker, M., Verhey, F. R. J., Vos, S. J. B., de Vugt, M. E., & van Boxtel, M. P. J. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4700 · Cited by 208 · cited 1×
“In a 16-year observational study of 949 individuals using the Lifestyle for Brain Health (LIBRA) measure of modifiable risk factors, a 1-point increase in LIBRA score was associated with a 19% greater risk of dementia.(11) In a metaanalyses of 19 studies, cognitive leisure activities,(12) including crossword puzzles,…”
BackgroundIn-MINDD Team, O’Donnell, C. A., Browne, S., Pierce, M., McConnachie, A., Deckers, K., van Boxtel, M. P. J., Manera, V., Köhler, S., Redmond, M., et al. (2015) · Pilot and Feasibility Studies · doi:10.1186/s40814-015-0035-x · Cited by 31 · cited 8×
“Because there appear to be multiple pathways to developing AD, there may also be multiple ways to prevent or delay the onset of AD.”
BackgroundInfluential
Cited by
Jo, T., Nho, K., & Saykin, A. J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00220 · Cited by 724
“Thus, a great deal of effort has been made to develop strategies for early detection, especially at pre-symptomatic stages in order to slow or prevent disease progression (Galvin, 2017; Schelke et al., 2018).”
BackgroundPistollato, F., Iglesias, R. C., Ruiz, R., Aparicio, S., Crespo, J., Lopez, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.012 · Cited by 247
The Effect of Baseline Patient and Caregiver Mindfulness on Dementia Outcomes
Innis, A. D., Tolea, M. I., & Galvin, J. E. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201292 · Cited by 18
“Alargenumberofmodifiable(e.g.,exposures, lifestyle, and social habits) and nonmodifiable (e.g., age, sex, genetics) risk factors has been identified [5–8].”
Self-citation
Metadata
- Authors
- Galvin, J. E.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2017-08-02
- Volume
- 65
- Issue
- 10
- Pages
- 2128-2133
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2740431289
- Cited by
- 92
- References
- 8
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.